High Potency Active Pharmaceutical Ingredients Market Holds The Largest Share, Estimated By Global Key Players Lonza, Pfizer Inc., Novartis International AG, BASF AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd.

High potency active pharmaceutical ingredients (HPAPIs) are small-molecule, biologic, or hybrids of antibody–drug conjugates, which link a cytotoxic small-molecule to a monoclonal antibody. Demand for high potency active pharmaceutical ingredients (HPAPIs) is rapidly increasing due to its ability to target diseased cells more precisely and selectively than other APIs and is regarded as a relatively more efficient treatment for cancer and chronic diseases such as diabetes and heart diseases, worldwide. According to estimates from the International Agency for Research on Cancer (IARC), in 2012, 14.1 million new cancer cases and 8.2 million cancer deaths were recorded worldwide. This global burden of cancer is expected to account for 21.7 million new cancer cases and cause 13 million deaths by 2030.

Get In-Depth Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/1336

Growing demand for Antibody Drug Conjugates (ADC) is expected to augment market growth

High potency active pharmaceutical ingredients is considered as a growing area for pharmaceutical manufacturers and contract manufacturing organizations (CMOs) with much R&D focusing on more specialized medicines especially in the field of oncology. According to IMS institute of healthcare informatics, 2016, 586 drugs are under development for oncology treatment, with over 70 new cancer treatments (for over 20 tumor types), entering the market over the past five years (2010-2015). HPAPIs are also increasingly being used in the form of Antibody Drug Conjugates (ADCs), which is an important and effective breakthrough in cancer treatment.

Increasing investment in research and development by manufacturers is expected to propel high potency active pharmaceutical ingredients market growth

Increasing number of major pharmaceutical companies are continuously focusing on expansion of their product line in HPAPIs or considering investing in new HPAPIs production facilities, further outsourcing the manufacturing of HPAPIs to contract manufacturers. This in turn will increase the benefits from the latter’s competency and expertise, as captive manufacturing of HPAPIs is expensive and requires stringent safety and handling specifications. This is thus expected to boost growth of the high potency active pharmaceutical ingredients market. The outsourcing of HPAPIs manufacturing is increasing in India, China, and Eastern European countries due to the low cost of manufacturing as compared to North America and Western Europe regions.

Among regions, North America holds the largest market share, followed by Europe in the global high potency active pharmaceutical ingredients market. The dominance of this region is due to high prevalence rate of cancer in the region, which in turn is increasing the potential of oncology drugs. For instance, according to an American Cancer Society estimations, 2017, 1,688,780 people are estimated to be diagnosed with cancer and 600,920 cancer deaths are estimated to occur in the US.

Market Key Players -

Key players in the high potency active pharmaceutical ingredients market include Lonza, Novartis International AG, BASF AG, Carbogen Amcis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd Bristol-Myers Squibb, Pfizer Inc., Roche Diagnostics., Boehringer Ingelheim, Covidien Plc, Merck & Co, Bayer AG, Sigma-Aldrich Corporation, and Sanofi Aventis.

High Potency Active Pharmaceutical Ingredients Market Taxonomy -

By Synthesis Route:

Synthetic
Biotech

By Therapeutic Applications:

Oncology
Hormonal Disorders
Glaucoma
Others

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1336

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.